ExonHit S.A. Company Profile
Exonhit (Alternext: ALEHT) is a biotech company, focused on personalized medicine, which develops targeted innovative therapeutic and diagnostic products, in oncology and Alzheimerâs disease. Exonhit has a balanced development strategy with internal development programs and strategic collaborations, in particular with Allergan.
News Articles
Exonhit to acquire InGen BioSciences for 18 million euros
French drug discovery and development firm Exonhit Therapeutics (ALEHT:FP) has entered into an agreement to acquire 100% of InGen BioSciences from its founders and financial shareholders, IPSA (ex-Inn...
Exonhit receives Oseo grant in cancer treatments consortium programme
Exonhit has been granted almost €2 million by Oseo as part of its involvement in a consortium led by ERYTECH Pharma and funded under Oseo’s Strategic Industrial Innovation programme. In addition t...
ExonHit completes private placement
ExonHit, InGen BioSciences deal
Erytech, ExonHit Share €8.9M Initial OSEO Funding for Enzyme Depletion Anticancer Project
Exonhit receives financial support from OSEO
Exonhit has received €1,928,000 from OSEO, as part of its involvement in a consortium led by ERYTECH Pharma and funded under the program for Strategic Industrial Innovation.
Exonhit, une petite levée pour un grand test
« Ne touchons pas à la loi TEPA, elle draine quelque 1 Mrd d’euros par an vers nos entreprises innovantes, ce n’est pas le moment…»
Drugs and Medications
None
PubMed Articles
RNA splicing is required to remove introns from pre-mRNA and alternative splicing generates protein diversity. Topoisomerase I (Top1) has been shown to be coupled with splicing by regulating SR splici...
Abstract Objective: Microarray-based signatures for clinical application are often plagued by processing variability or batch effects that compromise the robustness of the test performance. Methods: A...
Oxidative stress is known to be one of the major factors underlying Parkinson's disease (PD). One of the consequences of oxidative stress is lipid peroxidation. A toxic product of lipid peroxidation,...
Clinical Trials
None
Companies
Exonhit (Alternext: ALEHT) is a biotech company, focused on personalized medicine, which develops targeted innovative therapeutic and diagnostic products, in oncology and Alzheime...
Exonhit Therapeutics Incorporated
ExonHit Therapeutics is a functional genomics and drug discovery company that develops sophisticated and innovative gene-based therapeutics (Ready for Development Compounds - RDCs ) and diagnostic pro...
ExonHit is the world's leader in the analysis of alternative splicing. Alternative RNA splicing is an essential, naturally occurring biological process in which a single gene directs the production of...
ExonHit Therapeutics (Alternext: ALEHT) is a fast emerging healthcare player active in both therapeutics and diagnostics. The Company is applying its proprietary technology, based...
More Information about "ExonHit S.A." on BioPortfolio
We have published hundreds of ExonHit S.A. news stories on BioPortfolio along with dozens of ExonHit S.A. Clinical Trials and PubMed Articles about ExonHit S.A. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ExonHit S.A. Companies in our database. You can also find out about relevant ExonHit S.A. Drugs and Medications on this site too.
